RCEL.US Avita Medical Ltd

Healthcare Biotechnology USA Stocks
15.77 USD
Close of Nov 18, 2026
3.22 18.43
Market cap
USD 500M
P/E
-
P/B
11.77x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RCEL.US undervalued?

Graham number

The Graham number of Avita Medical Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Avita Medical Ltd fundamental analysis

No fundamental analysis for Avita Medical Ltd yet.

Avita Medical Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Avita Medical Ltd

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can…

Full company profile